Chikungunya infected children are being reported these days, said Dr. Deepal Perera, a specialist at the Lady Ridgeway ...

Valneva’s growth potential lies in Ixchiq, but risks remain. Find out why VALN stock is still a Buy with a good long-term ...

Cases of Chikungunya among children are being reported in recent days, Lady Ridgeway Hospital’s Consultant Paediatrician Dr. Deepal Perera said. Dr.

Valneva has announced positive outcomes from its Phase III VLA1553-321 trial of the single-shot IXCHIQ chikungunya virus ...

Seventy-two case have been diagnosed as confirmed GBS cases and 20 patients are currently on ventilators, according to health ...

This action follows an executive order signed by President Trump on his first day in office to withdraw the United States ...

Valneva’s vaccine was highly immunogenic in both dose groups. A full dose of the vaccine exhibited a more robust immune response compared to a half dose by providing protective antibody titers already ...

Pune: A 56-year-old woman in Maharashtra is suspected to have died of Guillain Barré syndrome (GBS) at Sassoon General ...

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported further positive Phase 3 data in adolescents for its single-shot chikungunya virus (CHIKV) vaccine, IXCHIQ®, ...

Valneva has shared positive results from a late-stage study of its single-dose chikungunya vaccine in adolescents aged 12 to ...

Valneva (VALN) stock rose after the company posted new Phase 3 trial data for its chikungunya vaccine, Ixchiq, in adolescents aged 12-17. Read more here.